Peter Hentschel appointed as Chairman at CytaCoat

Peter Hentschel appointed as Chairman at CytaCoat

Peter Hentschel appointed as Chairman at CytaCoat February 04, 2022   CytaCoat AB, developers of the unique CytaCoat anti-microbial coating technology, have appointed Peter Hentschel as Chairman. Peter brings a wealth of knowledge from his highly relevant and...
CYTACOAT ANNOUNCES APPOINTMENT OF GRAEME BROOKES AS CEO

CYTACOAT ANNOUNCES APPOINTMENT OF GRAEME BROOKES AS CEO

CytaCoat announces appointment of Graeme Brookes as CEO June 22, 2021   CytaCoat AB, developers of the unique CytaCoat anti-microbial coating technology, have appointed Graeme Brookes as Chief Executive Officer.  Graeme’s appointment further strengthens the...
CytaCoat coating inactivates SARS-CoV-2 (COVID-19)

CytaCoat coating inactivates SARS-CoV-2 (COVID-19)

CytaCoat coating inactivates SARS-CoV-2 (COVID-19) Press release Stockholm, July 9, 2020   The study was performed by the University of Tennessee Health Science Center (UTHSC) Regional Bioconception Laboratory, in May 2020. Silicone with and without CytaCoat...
CytaCoat awarded a Seal of Excellence in EIC Accelerator

CytaCoat awarded a Seal of Excellence in EIC Accelerator

Project name: CYTAMED   “The project “A universal life-saving protection for medical devices – a new tool for reduction of hospital infections in the global battle against antibiotic resistance”, proposal 946737, was awarded a “Seal of Excellence” in November...
CytaCoat secured grant from Vinnova the Swedish innovation Agency

CytaCoat secured grant from Vinnova the Swedish innovation Agency

Vinnova grants   CytaCoat has secured four grants from Vinnova, the Swedish innovation agency, total amount of approximately €750 k. The latest grant was received in March 2020 (€160 k). The idea of the project emerged responding to the need of reducing the...